Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 8/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30307615 | 0.95 | OPRM1 (0.46) | CAPN1CTSBOPRM1OPRD1CALCRL | |
| SCHEMBL29760917 | 0.94 | CAPN1 (0.54) | CAPN1CTSBCALCRL | |
| SCHEMBL31259022 | 0.92 | CAPN1 (0.52) | CAPN1CTSBOPRM1OPRD1CALCRL | |
| SCHEMBL29554458 | 0.91 | CAPN1 (0.54) | CAPN1CTSBOPRM1OPRD1CALCRL | |
| SCHEMBL32677766 | 0.91 | CAPN1 (0.48) | CAPN1CTSBOPRM1OPRD1CALCRL | |
| SCHEMBL32677764 | 0.91 | CAPN1 (0.48) | CAPN1CTSBOPRM1OPRD1CALCRL | |
| SCHEMBL29760912 | 0.90 | CAPN1 (0.54) | CAPN1CTSBOPRM1OPRD1CALCRL | |
| SCHEMBL29691750 | 0.90 | CAPN1 (0.54) | CAPN1CTSBOPRM1OPRD1CALCRL | |
| SCHEMBL29358088 | 0.90 | APLNR (0.46) | CAPN1OPRM1OPRD1APLNRBDKRB2 | |
| SCHEMBL29760911 | 0.89 | CAPN1 (0.56) | CAPN1CTSBCALCRLCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12453823-B2 | Autoinjector | Sanofi-Avents Deutschland GmbH (DE) | 2025-10-28 | — | — | US | disclosed |
| US-12440152-B2 | Supplementary device for a manually operable injection device | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2025-10-14 | — | — | US | disclosed |
| US-20250213795-A1 | Autoinjector | SANOFI AVENTIS DEUTSCHLAND (DE) | 2025-07-03 | — | — | US | disclosed |
| US-20250152846-A1 | AUTOINJECTOR | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2025-05-15 | — | — | US | disclosed |
| US-12251548-B2 | Medicament delivery device with use indicator | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2025-03-18 | — | — | US | disclosed |
| US-12220444-B2 | Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39) | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-02-11 | — | — | US | disclosed |
| US-20240342375-A1 | Medicament Delivery Device and Actuation Mechanism for a Drug Delivery Device | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2024-10-17 | — | — | US | disclosed |
| US-20240342385-A1 | Auto-Injector | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2024-10-17 | — | — | US | disclosed |
| WO-2023231433-A1 | LONG-ACTING EXENDIN-9-39 AND USE THEREOF IN HYPOGLYCEMIA TREATMENT AND AS DRUG FOR TREATING HYPOGLYCEMIA | 南京盛德瑞尔医药科技有限公司 | 2023-12-07 | — | — | WO | disclosed |
| US-20230346890-A1 | TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA WITH GLP-1 ANTAGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| US-11419918-B2 | Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide | SHENZHEN TURIER BIOTECH CO., LTD. | 2022-08-23 | — | — | US | disclosed |
| US-20220241511-A1 | Injection Device | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2022-08-04 | — | — | US | disclosed |
| US-20220096005-A1 | Supplementary Device for a Manually Operable Injection Device | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11419918-B2 | Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide | GCGR, GLP1R, GIPR | CAPN1 2190/4885CTSB 751/4885OPRM1 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.